How Much Does Morpheus8 Cost?

The reason nobody can tell you what Morpheus8 costs is that Morpheus8 is not one thing. It is a console with four interchangeable applicator tips, a treatment depth that runs from half a millimeter to four, and an energy ceiling that changes which patients can be treated at full power.

Those specifications are not marketing copy. They are in the two 510(k) files InMode holds with the Food and Drug Administration. K192695, cleared in December 2019, covers the InMode System with the Morpheus8 (Fractora) Applicators. K240017, cleared on 13 June 2024, covers the InMode System with the Morpheus8 90 Applicator. Both are Class II devices under 21 CFR 878.4400, electrosurgical cutting and coagulation, product code GEI. Between them they define what this radiofrequency microneedling platform was cleared to do, and the two definitions are not identical.

What FDA cleared: electrocoagulation and hemostasis in K192695, coagulation or contraction of soft tissue in K240017

The indications for use statements are the whole of what FDA signed off on, and the two clearances differ in a way that matters.

K192695 states the InMode System with the Morpheus8 (Fractora) Applicators "is intended for use in Dermatologic and General Surgical procedures for Electrocoagulation and Hemostasis." The phrase "contraction of soft tissue" does not appear in it. K240017, covering the Morpheus8 90 Applicator, states that device "is intended for use in dermatological procedures where coagulation/contraction of soft tissue or hemostasis is needed." Soft tissue contraction entered the cleared language with the 2024 submission, and it is scoped to that applicator.

Both statements carry an identical restriction: at energy levels greater than 62 mJ per pin, use of the applicator is limited to Skin Types I to IV. That is a Fitzpatrick constraint written into the clearances themselves, not a clinic preference, and it is the single most consequential line in either document for an intake conversation.

What the indications do not say is also factual. Neither statement names collagen, wrinkles, acne scarring, cellulite, jowls or body contouring. Those may be reasonable clinical expectations and are widely discussed in the literature, but they are not the cleared indications, and a practice describing them should know which of the two things it is doing.

A 510(k) clearance is a substantial-equivalence finding, and the K192695 file records no clinical performance data

The difference between "FDA cleared" and "FDA approved" is not pedantry; it is a different legal pathway with a different evidentiary burden.

Under 510(k), a manufacturer demonstrates that its device is substantially equivalent to a legally marketed predicate. For K192695 the predicate was the InMode System with the Fractora3D/3D-90 Applicators, cleared under K180189. The 510(k) summary for K192695 lists its evidence categories explicitly: non-clinical bench performance data comparing pulse duration, energy per pin, total energy and peak-to-peak voltage against the predicate. Under "Animal Performance Data / Histology Data" it records "Not Applicable." Under "Clinical Performance Data" it records "Not Applicable."

FDA's clearance letter adds that issuance of a substantial equivalence determination "does not mean that FDA has made a determination that your device complies with other requirements of the Act," and reminds the manufacturer that "device labeling must be truthful and not misleading." None of that makes the device ineffective, and bench-only submissions are routine for this device class. It means the clearance answers a question about equivalence to a predicate, and a caller who has been told "it is FDA approved" has been told something slightly different from what the file contains.

The price varies because the treatment varies: four tips, 4 mm of depth, and no session count anywhere in the clearance

The technical specifications in K192695 explain the quote spread better than any pricing guide.

The system comprises four applicator tip heads: a 24-pin tip carried over from the predicate, plus new 12-pin, 40-pin and T tips. Pin count ranges from 12 to 40. Maximum treatment depth is 4.0 mm, except for the T tip, which is fixed at 0.5 mm. The console delivers up to 65 watts of radiofrequency output at 1 MHz, and every tip head is single-use and gamma sterilized.

• A single-use tip is a disposable per-treatment cost, and a 40-pin tip is not the same consumable as a 12-pin tip.

• Treatment depth selection changes the clinical procedure, the time required and often the provider performing it.

• Area matters: a periorbital pass and a full abdomen are the same device and different appointments.

• Nothing in either clearance specifies a number of sessions. Session count is a clinical and commercial decision made at the practice, which is why packages differ between two clinics running identical hardware.

So a published "Morpheus8 price" that does not state tip, depth, area and session count is describing an unspecified quantity. That is why a caller comparing two quotes frequently finds a wide gap and concludes one practice is overcharging, when the likelier explanation is that the two quotes cover different treatments.

The Skin Type I to IV energy limit is an intake question, not a consult-room question

FDA's two Morpheus8 clearances both restrict use of the applicator to Fitzpatrick Skin Types I to IV at energy levels above 62 mJ per pin. A prospective patient with a higher Fitzpatrick type is not excluded from the device, but the energy available to treat her is constrained in a way that can affect both the plan and the price.

A front desk should not be assessing anyone's skin type, and is not in a position to say whether a given patient is a candidate. What it can do is recognize that the question exists and route accordingly, rather than quoting a package price that may not apply and then walking it back in the consult room. Recognizing a question is not answering it, and the distinction is the whole job at intake.

Illustrative model - not a client result or guarantee. Picture a medspa fielding twenty-five device inquiries a month, a share of which arrive in the evening after someone has read a pricing guide. Those evening calls reach the same recording whether the caller is asking about a periorbital pass or a full abdomen. The model assumes nothing about conversion or package value. It assumes only that the question gets asked after hours at a similar rate to during them, which is a thing the practice's own call log can confirm or refute in ten minutes.

What a medspa front desk can state about Morpheus8 pricing without guessing

A medspa front desk can give an accurate answer about Morpheus8 pricing that quotes no figure at all and still leaves the caller better informed than the pricing guide she just read.

That answer establishes that pricing depends on treatment area, depth and the number of sessions planned, so a single figure would be misleading. It states that this practice quotes per session or per package, whichever is true. It notes that the device is FDA cleared rather than FDA approved, under 510(k) submissions covering electrocoagulation, hemostasis and, for the 90 applicator, contraction of soft tissue. And it books the consult as the step that produces a real number, because that is what the consult is for.

Written down, that is four sentences. Unwritten, it is four different improvisations across a week, and the practice has no way of knowing which version it is selling. That is what a structured intake layer fixes: it does not diagnose, it does not quote, it captures what the caller asked for and routes it to someone who can price it properly, at whatever hour the caller happened to be reading. Rosey handles that first conversation on medspa lines.

Frequently asked questions

How much does Morpheus8 cost? There is no single figure, and the reason is structural. Pricing depends on applicator tip, treatment depth, body area and the number of sessions planned, none of which are specified in the device's FDA clearances. Two practices running identical hardware can quote very different totals for different treatments.

Is Morpheus8 FDA approved? It is FDA cleared, not approved. FDA cleared the InMode System with the Morpheus8 (Fractora) Applicators under 510(k) K192695 in December 2019 and the InMode System with the Morpheus8 90 Applicator under K240017 on 13 June 2024. A 510(k) is a determination of substantial equivalence to a legally marketed predicate device.

What is Morpheus8 cleared to treat? The two clearances differ. K192695 states the device is intended for Dermatologic and General Surgical procedures for electrocoagulation and hemostasis. K240017, covering the Morpheus8 90 Applicator, states it is intended for dermatological procedures where coagulation, contraction of soft tissue or hemostasis is needed.

Is there a skin type restriction? Yes, and it is in both clearances. At energy levels greater than 62 mJ per pin, use of the applicator is limited to Skin Types I to IV.

How deep does Morpheus8 go? K192695 lists a maximum treatment depth of 4.0 mm for the device, with the T tip head fixed at 0.5 mm.

What clinical data supported the 2019 clearance? The 510(k) summary for K192695 records "Not Applicable" under both Animal Performance Data / Histology Data and Clinical Performance Data. The submission relied on non-clinical bench performance testing against the predicate device K180189.

Where this fits

A device question is a pricing question wearing a technical costume, and it arrives on the same line as everything else. The caller who asks what Morpheus8 costs is at exactly the point where the first leak point opens. The same pattern runs through what a caller expects from an injectable consultation, the questions medspa prospects actually open with, how quickly a practice answers a new inquiry, and what changes when something structured answers instead of a recording. Whether a practice is ready for that is the subject of the readiness question.

You already own the device. Your clinical team already knows which depths and areas it treats. What is less certain is whether the person answering at 7pm can describe the pricing structure without inventing a number.

This article describes device regulatory status from primary FDA documents. It is not medical advice, does not recommend any treatment, and does not assess candidacy. Those decisions belong with a licensed clinician.

References

• U.S. Food and Drug Administration, 510(k) K192695, "InMode System with the Morpheus8 (Fractora) Applicators," clearance letter dated 27 December 2019 and accompanying 510(k) summary - indications for use, the 62 mJ per pin Skin Type I-IV limitation, Class II classification under 21 CFR 878.4400 product code GEI, predicate device K180189, the four applicator tip heads, 4.0 mm maximum treatment depth with the T tip fixed at 0.5 mm, 65 W maximum RF output at 1 MHz, and the "Not Applicable" entries for animal and clinical performance data.

• U.S. Food and Drug Administration, 510(k) K240017, "InMode System with the Morpheus8 90 Applicator," clearance letter dated 13 June 2024 - indications for use including coagulation/contraction of soft tissue, the 62 mJ per pin Skin Type I-IV limitation, and the Class II / 21 CFR 878.4400 / product code GEI classification.

• U.S. Food and Drug Administration, standard 510(k) clearance letter language on substantial equivalence and the requirement that device labeling be truthful and not misleading, as reproduced in both letters above.

Next Step

If your premium practice runs more than 100 inbound consult inquiries a month and has no structured measurement of how many never reach a scheduled consultation, your pipeline is leaking revenue. We quantify this for your practice in a 30-minute Intake Leak Audit.

• Request an Intake Leak Audit: expand@thethinkingrobot.com

• Audit Real-Time Conversational Velocity: Talk to Rosey, our AI receptionist, at +1 (720) 776-1664.